Chembio Diagnostics, Inc. becomes the first North American structure controlled by Biosynex in North America STRASBOURG, France, April 27, 2023 (GLOBE NEWSWIRE) -- Biosynex SA ("Biosynex") (EPA: ALBIO), a French market leader specializing in the design and distribution of rapid tests, today announced it has completed its acquisition of Chembio Diagnostics, Inc. ("Chembio"), a leading point-of-care diagnostics company focused on infectious diseases. Chembio is now part of Biosynex Group. The complementary nature of the technologies and product portfolio as well as the combination of market opportunities will be important growth drivers for the combined company. In addition, significant ope

MEDFORD, N.Y., April 19, 2023 (GLOBE NEWSWIRE) -- Chembio Diagnostics, Inc. (NASDAQ:CEMI), a leading point-of-care diagnostics company focused on infectious diseases, today released the following letter to stockholders concerning the pending tender offer by Biosynex SA. April 19, 2023 Fellow Chembio Stockholders, We strongly urge you to tender your shares of common stock of Chembio Diagnostics Inc. ("Chembio") in the tender offer being made by Biosynex SA ("Biosynex") and its affiliates. The tender offer is the first step in a proposed merger between Chembio and Biosynex. Biosynex has agreed to pay $0.45 per share in cash to each of our stockholders who tender their shares prior t

STRASBOURG, France, April 13, 2023 (GLOBE NEWSWIRE) -- Biosynex SA ("Biosynex") (EPA: ALBIO), a French market leader specializing in the design and distribution of rapid tests, today announced that Project Merci Merger Sub, Inc. ("Purchaser"), a Nevada corporation and its wholly-owned indirect subsidiary, has extended the expiration time for the previously announced tender offer to purchase all of the issued and outstanding shares of common stock (the "Shares") of Chembio Diagnostics, Inc. (NASDAQ:CEMI) ("Chembio") at a price of $0.45 per Share, net to the seller in cash, without interest and subject to any required tax withholding, until 6:00 p.m., New York City time on April 26, 2023, un

Colliers Securities downgraded Chembio Diagnostics from Buy to Neutral

Colliers Securities resumed coverage of Chembio Diagnostics with a rating of Buy and set a new price target of $8.00

4 - CHEMBIO DIAGNOSTICS, INC. (0001092662) (Issuer)

4 - CHEMBIO DIAGNOSTICS, INC. (0001092662) (Issuer)

4 - CHEMBIO DIAGNOSTICS, INC. (0001092662) (Issuer)

15-12G - CHEMBIO DIAGNOSTICS, INC. (0001092662) (Filer)

EFFECT - CHEMBIO DIAGNOSTICS, INC. (0001092662) (Filer)

EFFECT - CHEMBIO DIAGNOSTICS, INC. (0001092662) (Filer)

HAUPPAUGE, N.Y., Jan. 05, 2022 (GLOBE NEWSWIRE) -- Chembio Diagnostics, Inc. (Nasdaq: CEMI), a leading point-of-care diagnostics company focused on infectious diseases, today announced the appointment of Larry Steenvoorden as Chief Financial Officer effective immediately. "We are thrilled to welcome Larry to the Chembio executive leadership team. Larry has developed valuable insights over his 25 years of financial leadership experience, spanning accounting, budgeting, public company reporting, business development, and commercial strategy. Those skills will be critical to our success as we scale our business in support of our corporate growth and operational objectives," said Richard Eber

NEW YORK, Dec. 9, 2020 /PRNewswire/ -- The current pandemic has been devastating for the global economy and has caused severe backlogs in hospitals. Additionally, a spike in demand for Personal Protective Equipment (PPE) and new disinfecting technologies has also been seen. For example, when it comes for PPE, the global market was valued at USD 52.7 Billion in 2019 and is expected to reach USD 92.5 Billion by 2025 while growing at a CAGR of 8.7% during 2020-2025, according to VynZ Research. As for new technologies for disinfection, a recent example comes from LG Electronics, which announced on Wednesday the launch of a disinfection robot that will assist in containing the spread of the vi

Chembio Diagnostics, Inc. becomes the first North American structure controlled by Biosynex in North America STRASBOURG, France, April 27, 2023 (GLOBE NEWSWIRE) -- Biosynex SA ("Biosynex") (EPA: ALBIO), a French market leader specializing in the design and distribution of rapid tests, today announced it has completed its acquisition of Chembio Diagnostics, Inc. ("Chembio"), a leading point-of-care diagnostics company focused on infectious diseases. Chembio is now part of Biosynex Group. The complementary nature of the technologies and product portfolio as well as the combination of market opportunities will be important growth drivers for the combined company. In addition, significant ope

HAUPPAUGE, N.Y., Nov. 03, 2022 (GLOBE NEWSWIRE) -- Chembio Diagnostics, Inc. ("Chembio" or the "Company") (NASDAQ:CEMI), a leading point-of-care diagnostics company focused on infectious diseases, today reported financial results for the quarter ended September 30, 2022. Recent Highlights Achieved third quarter 2022 total revenue of $11.2 million including product revenue of $10.8 million, representing product revenue growth of 16% compared to the prior year periodU.S. product revenue of $4.8 million grew 361% compared to the prior year periodAwarded $3.2 million contract from the CDC for development and clinical validation of Dual-Path Platform (DPP) Syphilis Treponemal Nontreponemal (

HAUPPAUGE, N.Y., Oct. 20, 2022 (GLOBE NEWSWIRE) -- Chembio Diagnostics, Inc. (NASDAQ:CEMI), a leading point-of-care diagnostics company focused on infectious diseases, announced today that it will release financial results for the third quarter of 2022 after the close of trading on Thursday, November 3, 2022. The company's management team will host a corresponding conference call beginning at 4:30 p.m. Eastern Time on November 3, 2022. Investors interested in listening to the conference call may do so by dialing 888-506-0062 from the US or 973-528-0011 from outside the US and providing Entry Code: 600643 or by accessing www.chembio.com/investors/calendar-of-events/. A replay of the call

SC 13D/A - CHEMBIO DIAGNOSTICS, INC. (0001092662) (Subject)

SC 13D - CHEMBIO DIAGNOSTICS, INC. (0001092662) (Subject)

SC 13D - CHEMBIO DIAGNOSTICS, INC. (0001092662) (Subject)